Study record
NMN and glucose/lipid metabolism: meta-analysis finds no benefit (2024/2025)
Human RCT — biomarker endpoint (meta-analysis, null)
○ Evidence tier 4 — Human RCT — biomarker endpoint
Record verify: primary source pending
| Design | Systematic review and meta-analysis of randomized controlled trials |
| DOI | 10.1007/s11892-024-01557-z |
| Citation status | doi verified via Crossref 2026-07-12 (Curr Diab Rep 2025;25, 'Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials'). A second concordant meta-analysis (Crit Rev Food Sci Nutr 2025;65:4382-4400, doi 10.1080/10408398.2024.2387324) reaches a similar null conclusion. PMID: needs_primary_fulltext. |
Five-qualifier claim
| Species / population | Adults pooled across randomized controlled trials of NMN (systematic review and meta-analysis). |
| Exposure, route, schedule | Oral NMN across included RCTs (varied doses/durations). |
| Comparator / duration | Placebo-controlled RCTs pooled; meta-analytic synthesis. |
| Endpoint / numeric result | No statistically significant effect of NMN on glucose or lipid metabolism across the pooled RCTs. |
| What it did NOT establish | A null meta-analysis for metabolic biomarkers — it does not support a metabolic, functional, or lifespan benefit of NMN. |
Interventions
Primary reference
https://doi.org/10.1007/s11892-024-01557-z
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.